GlassScriptPhysician profile
John Frank Dishuck
NPI 1225019706
$8,510.89
in general payments reported to CMS, 2019-2025
25 companies · $2,499 in 2025
The $2,499 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.24 · 2021: $490 · 2022: $1,674 · 2023: $1,963 · 2024: $1,858 · 2025: $2,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,286 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,285.65 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,806.36 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,748.37 | 2021-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $947.19 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $793.14 | 2022-2025 | Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $636.09 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $616.90 | 2021-2025 | |
| Amgen INC. | $345.51 | 2021-2025 | Tezspire |
| Pfizer INC. | $275.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.27 | 2021-2022 | |
| Optinose US, INC. | $231.92 | 2021-2025 | |
| Genentech USA, INC. | $138.72 | 2023-2025 | Xolair |
| Grifols USA, LLC | $134.26 | 2022-2023 | Xembify |
| Kaleo, INC. | $125.81 | 2021-2023 | Auvi-Q |
| Hikma Pharmaceuticals USA | $72.92 | 2023-2025 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $63.61 | 2025 | Neffy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $51.00 | 2020-2021 | |
| Galderma Laboratories, L.P. | $49.53 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $47.47 | 2022 | |
| Blueprint Medicines Corporation | $46.05 | 2023 | Ayvakit |
| Merck Sharp & Dohme LLC | $32.41 | 2021-2023 | |
| Sanofi Pasteur INC. | $29.57 | 2023 | |
| Ionis Pharmaceuticals, INC. | $21.14 | 2025 | Dawnzera |
| Dermavant Sciences, INC. | $18.12 | 2024 | Vtama |
| Jubilant Hollisterstier LLC | $16.72 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.28 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dishuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.